Dynamic 3D-MR mammography: is there a benefit of sophisticated evaluation of enhancement curves for clinical routine?
The purpose of the study was to compare standard analysis with pharmacokinetic analysis of time-intensity curves in dynamic three-dimensional (3D) MR mammography (MRM) for their capability of differentiating benign from malignant disease. Dynamic MRM of the whole breast was performed at 1.0 T using an axial fast low-angle shot (FLASH) 3D sequence. For the standard evaluation, the enhancement of the first minute (E1) and the slope of enhancement from minute 2 to 10 (SE2-10) were calculated. For pharmacokinetic analysis, the amplitude of enhancement (A), distribution time (t21), and elimination time (tel) were computed. Sixty-two histologically verified lesions were evaluated. The standard evaluation methods yielded a highly significant difference between benign and malignant disease for E1 (P = .0008) and SE2-10 (P = .0001). The pharmacokinetic parameters gained similarly significant P values (A, P = .0014; t21, P = .0024; tel, P = .0001). Both standard and pharmacokinetic analysis concordantly discriminated between benign and malignant lesions in discriminant analysis. Compared with standard analysis, a pharmacokinetic analysis of time-intensity curves is not beneficial for routine clinical diagnosis.